DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H2 2016" report to their offering.
Herpes Zoster (Shingles) pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 4, 2, 7 and 2 respectively.
Herpes Zoster (Shingles) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Herpes Zoster Overview
- Therapeutics Development
- Pipeline Products for Herpes Zoster - Overview
- Pipeline Products for Herpes Zoster - Comparative Analysis
- Herpes Zoster - Therapeutics under Development by Companies
- Herpes Zoster - Therapeutics under Investigation by Universities/Institutes
- Herpes Zoster Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Herpes Zoster - Products under Development by Companies
- Herpes Zoster - Products under Investigation by Universities/Institutes
- Herpes Zoster - Companies Involved in Therapeutics Development
- Astellas Pharma Inc.
- Beijing Minhai Biotechnology Co., Ltd
- ContraVir Pharmaceuticals, Inc.
- Epiphany Biosciences, Inc.
- Foamix Pharmaceuticals Ltd.
- GeneOne Life Science, Inc.
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- N & N Pharmaceuticals Inc.
- NAL Pharmaceuticals Ltd.
- NanoViricides, Inc.
- ReceptoPharm, Inc.
- TSRL, Inc.
- XBiotech Inc
For more information about this report visit http://www.researchandmarkets.com/research/bqqdpc/herpes_zoster
